Area of research
Genetics · Cancer Research
Research interest
Research interests include Coagulation, Bradykinin, Polyphosphates, and Angioedema, MicroRNA in disease regulation, RNA modifications and cancer, and Cancer-related molecular mechanisms research.
Loss of METTL3 m6A methyltransferase results in short-term progression and poor treatment outcome of bladder cancer patients.
LncRNAs in Ovarian Cancer: Emerging Insights and Future Perspectives in Tumor Biology and Clinical Applications.
Unraveling small non-coding RNAs with a significant post-transcriptional impact on breast cancer cell signaling, using a combinational sequencing approach.
Delving into tRNA-derived small RNAs in multiple myeloma: elevated 3'U-tRF<sup>SerTGA</sup> leads to poor disease prognosis.
Identification of Novel Alternative Transcripts of the Human ALKBH Gene Family and Investigation of Their Unique Expression Signatures in Cancer Cells.
Time- and dose-dependent regulation of circular RNAs in the response of triple-negative breast cancer cells to ionizing radiation.
Integrating Artificial Intelligence in Next-Generation Sequencing: Advances, Challenges, and Future Directions.
Non-Coding RNAs in Health and Disease: From Biomarkers to Therapeutic Targets
RNA-Targeting Techniques: A Comparative Analysis of Modern Approaches for RNA Manipulation in Cancer Research and Therapeutics.
Regulation of biomarker analysis: what can be translated in the clinic?
Discovery of circular transcripts of the human BCL2-like 12 (BCL2L12) apoptosis-related gene, using targeted nanopore sequencing, provides new insights into circular RNA biology.
NEAT1 lncRNA overexpression results in short-term progression and poor treatment outcome in childhood B-ALL.
Deciphering the m6A Epitranscriptomic Landscape of mRNAs in Breast Cancer Cells.
Targeted nanopore sequencing for the identification of novel <i>PRMT1</i> circRNAs unveils a diverse transcriptional profile of this gene in breast cancer cells.
Small RNA-seq and clinical evaluation of tRNA-derived fragments in multiple myeloma: Loss of mitochondrial i-tRF<sup>HisGTG</sup> results in patients' poor treatment outcome.
<i>MIR145</i> Core Promoter Methylation in Pretreatment Cell-Free DNA: A Liquid Biopsy Tool for Muscle-Invasive Bladder Cancer Treatment Outcome.
ciRS-7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myeloma.
Kallikrein-related peptidases: mechanistic understanding for potential therapeutic targeting in cancer.
Small non-coding RNAs as diagnostic, prognostic and predictive biomarkers of gynecological cancers: an update.
Beyond the Chromosome: Recent Developments in Decoding the Significance of Extrachromosomal Circular DNA (eccDNA) in Human Malignancies.
New insights into the dynamics of m6A epitranscriptome: hybrid-seq identifies novel mRNAs of the m6A writers METTL3/14.
Exploring the time-dependent regulatory potential of microRNAs in breast cancer cells treated with proteasome inhibitors.
Recent Advances in Genome-Engineering Strategies.
Unveiling the Human Gastrointestinal Tract Microbiome: The Past, Present, and Future of Metagenomics.
The Repertoire of RNA Modifications Orchestrates a Plethora of Cellular Responses.
Epi-miRNAs: Modern mediators of methylation status in human cancers.
miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma.
Preoperative Cell-Free DNA (cfDNA) in Muscle-Invasive Bladder Cancer Treatment Outcome.
Next-generation sequencing reveals altered gene expression and enriched pathways in triple-negative breast cancer cells treated with oleuropein and oleocanthal.
Association of high miR-27a, miR-206, and miR-214 expression with poor patient prognosis and increased chemoresistance in triple-negative breast cancer.
PubMed 2023cited by 7position: middle